Free Webinar | SARS-CoV-2 Neutralizing Antibody Testing for Vaccine Efficacy Assessment

May 5, 2021 | 1:00 – 2:00 pm EDT

The COVID-19 pandemic, caused by SARS-CoV-2, has severely impacted the world and our home country. In record time, three vaccines by Pfizer, Moderna and Janssen have been authorized for emergency use by the Food and Drug Administration. Despite significant research and clinical advances made to combat the SARS-CoV-2 virus, the emergence of new variants and community outbreaks are of continued concern. Biodesix and GenScript have come together to offer the cPass™ SARS-CoV-2 Neutralizing Antibody Test as a service, which uses ELISA technology to qualitatively detect neutralizing antibodies to the receptor binding domain (RDB) in the spike protein of SARS-CoV-2. This assay is currently highly applicable for research use to further assess the level of protection that these novel vaccines offer between individuals as well as the appropriate timing required between doses or boosters.

Register for our webinar on May 5, 2021 to:

  • Understand the principles of the cPass surrogate virus neutralization test (cPass sVNT) and how it compares to the gold standard live cell virus neutralization tests.
  • Learn how cPass sVNT is distinguished from IgG binding antibody assays in delineating between vaccinated individuals and how these data compare with published vaccine efficacy data.
  • Understand processes and workflows for integrating cPass sVNT into a high-complexity CLIA laboratory.
  • Learn about clinical studies and applications of cPass sVNT in the real-world and for biopharmaceutical research.


Laura J. Peek, PhD, Vice President, Laboratory Operations, De Soto, Biodesix, Inc.

Sean Taylor, MBA, PhD, Field Application Scientist Manager, North America, GenScript

Speaker Biographies

Laura J. Peek, PhD
Vice President, Laboratory Operations, De Soto, Biodesix, Inc.

Laura J. Peek, PhD, leads the Kansas laboratory of Biodesix, Inc., a clinical laboratory focused on data-driven diagnostic solutions in lung disease and beyond. Dr. Peek is the New York State Clinical Laboratory Evaluation Program (CLEP) Laboratory Director of the CLIA/COLA-accredited Kansas-based clinical laboratory. Under her supervision, the laboratory performs COVID-19 antibody testing as well as Nodify Lung testing, which helps physicians assess the risk of malignancy of a pulmonary nodule. Dr. Peek received her PhD in Pharmaceutical Chemistry from The University of Kansas and conducted post-doctoral training in Chemical Engineering and Pharmaceutical Chemistry from The University of Kansas.

Sean Taylor, MBA, PhD
Field Application Scientist Manager, North America, GenScript

Sean Taylor, MBA, PhD, graduated from McGill University and has spent the past ten years publishing articles and providing seminars, workshops and training videos to help the global scientific community achieve excellent data from western blotting, qPCR and digital PCR experiments. He has managed teams of Field Application Scientists (FAS) in Canada for over a decade who have helped thousands of scientists achieve their research goals. In his current role as North American FAS Manager for GenScript, he has also been supporting the novel cPass SARS-CoV-2 assay with the development of quantitative and automation protocols. He leads a dedicated team to continue the tradition of providing pertinent and timely information to help the scientific community overcome research hurdles to accelerate the production of high quality, publishable data cost-effectively.